1. Home
  2. REGN

REGN

Regeneron Pharmaceuticals Inc.

Logo Regeneron Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Founded: 1988 Country:
United States
United States
Employees: N/A City: TARRYTOWN
Market Cap: 98.4B IPO Year: 1991
Target Price: $973.17 AVG Volume (30 days): 469.2K
Analyst Decision: Buy Number of Analysts: 24
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 34.77 EPS Growth: -9.03
52 Week Low/High: $684.81 - $998.33 Next Earning Date: 05-02-2024
Revenue: $13,117,200,000 Revenue Growth: 7.76%
Revenue Growth (this year): 8.29% Revenue Growth (next year): 7.50%

Share on Social Networks:

Stock Insider Trading Activity of Regeneron Pharmaceuticals Inc. (REGN)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
MURPHY ANDREW J REGN EVP Research Mar 13 '24 Sell $968.20 196 $189,767.20 48,306 SEC Form 4
MURPHY ANDREW J REGN EVP Research Mar 13 '24 Sell $966.30 17 $16,427.10 48,502 SEC Form 4
MURPHY ANDREW J REGN EVP Research Mar 13 '24 Sell $965.51 78 $75,309.78 48,519 SEC Form 4
MURPHY ANDREW J REGN EVP Research Mar 13 '24 Sell $962.87 1 $962.87 48,597 SEC Form 4
MURPHY ANDREW J REGN EVP Research Mar 13 '24 Sell $961.74 47 $45,201.78 48,598 SEC Form 4
MURPHY ANDREW J REGN EVP Research Mar 13 '24 Sell $951.92 182 $173,249.44 53,907 SEC Form 4
MURPHY ANDREW J REGN EVP Research Mar 13 '24 Sell $952.40 444 $422,865.60 53,463 SEC Form 4
MURPHY ANDREW J REGN EVP Research Mar 13 '24 Sell $953.77 576 $549,371.52 52,887 SEC Form 4
MURPHY ANDREW J REGN EVP Research Mar 13 '24 Sell $954.66 870 $830,554.20 52,017 SEC Form 4
MURPHY ANDREW J REGN EVP Research Mar 13 '24 Sell $955.54 545 $520,769.30 51,472 SEC Form 4
MURPHY ANDREW J REGN EVP Research Mar 13 '24 Sell $956.34 1,108 $1,059,624.72 50,364 SEC Form 4
MURPHY ANDREW J REGN EVP Research Mar 13 '24 Sell $957.35 730 $698,865.50 49,634 SEC Form 4
MURPHY ANDREW J REGN EVP Research Mar 13 '24 Sell $958.34 477 $457,128.18 49,157 SEC Form 4
MURPHY ANDREW J REGN EVP Research Mar 13 '24 Sell $959.36 512 $491,192.32 48,645 SEC Form 4
LAROSA JOSEPH J REGN EVP General Counsel and Secret Feb 26 '24 Sell $990.00 1,000 $990,000.00 36,543 SEC Form 4
Fenimore Christopher R. REGN SVP Finance & CFO Feb 9 '24 Sell $955.00 600 $573,000.00 14,372 SEC Form 4
Fenimore Christopher R. REGN SVP Finance & CFO Feb 9 '24 Sell $954.57 1,100 $1,050,027.00 14,972 SEC Form 4
Fenimore Christopher R. REGN SVP Finance & CFO Feb 9 '24 Sell $953.47 1,342 $1,279,556.74 16,072 SEC Form 4
Fenimore Christopher R. REGN SVP Finance & CFO Feb 9 '24 Sell $952.62 1,046 $996,440.52 17,414 SEC Form 4
Fenimore Christopher R. REGN SVP Finance & CFO Feb 9 '24 Sell $951.39 487 $463,326.93 18,460 SEC Form 4
Fenimore Christopher R. REGN SVP Finance & CFO Feb 9 '24 Sell $950.49 344 $326,968.56 18,947 SEC Form 4
SING GEORGE L REGN Director Feb 8 '24 Sell $955.00 500 $477,500.00 26,349 SEC Form 4
SING GEORGE L REGN Director Feb 8 '24 Sell $945.00 500 $472,500.00 26,349 SEC Form 4
McCourt Marion REGN EVP Commercial Feb 5 '24 Sell $934.71 1,000 $934,710.00 13,789 SEC Form 4
McCourt Marion REGN EVP Commercial Feb 1 '24 Sell $945.61 273 $258,151.53 14,789 SEC Form 4